1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.

Key facts

Study ID

NCT04589403

Run by

Op-T LLC

People needed

14

Starts

2021-02-18

Expected to finish

2021-09-27

Last updated by the study team

2025-09-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• IMMUNOe Research — Centennial, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.